Relapsed, Indolent B-Cell Malignancies | Norton Healthcare

Indication: Relapsed, Indolent B-Cell Malignancies

A Phase 1a/1b Study of PSB202 in Patients with Previously Treated, Relapsed, Indolent B-Cell Malignancies

Sub-indication: Hematological Malignancies

Study Type: Drug Study

Principal Investigator: Don Stevens, M.D.
Norton Cancer Institute

Sponsor: Sponsor: Qilu Puget Sound Biotherapeutics

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.